Clinical Trials

A randomized, double blind, placebo-controlled, multi-center study in men with acquired hypogonadotropic hypogonadism to compare changes in body composition and metabolic parameters with diet and exercise in conjunction with treatment with 12.5 mg or 25 mg enclomiphene

Status: Active

Purpose: To compare the effects of treatment with enclomiphene to placebo, upon body composition and metabolic parameters in hypogonadal men undergoing a 6-month diet and 15 month exercise program.


  • Overweight males ages 18-60
  • Have secondary hypogonadism and confirmed morning testosterone levels less than or equal to 300ng/dL
  • Have a waist circumference of greater than or equal to 40 inches (101.6 cm)
  • Have not been treated with testosterone products in the 6 months prior to the study
  • Have not used testosterone products for a duration of a year or longer

Study Drug: Enclomiphene 12.5 and 25 mg capsules, and placebo

Study Design: Randomized, double blind, placebo-controlled, multi-center

Primary Outcome Measures:

  • Changes in body composition and metabolic parameters.

For more information, please visit or

If you meet the study criteria and are interested in participating, please try the “online screener” on or contact:

Study Director:
Repros Therapeutics Inc.®
800-895-6554ext 3403

Clinical Site Locations:

Little Rock


New Jersey
Garden City

New York


2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3446 fax